Eli Lilly 2012 Annual Report Download - page 57

Download and view the complete annual report

Please find page 57 of the 2012 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 164

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164

45
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions) Year Ended December 31 2012 2011 2010
Segment revenue—to unaffiliated customers
Human pharmaceutical products
Neuroscience. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 7,575.1 $ 9,723.8 $ 9,419.0
Endocrinology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,810.9 6,806.7 6,135.4
Oncology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,281.6 3,322.2 3,744.5
Cardiovascular. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,632.5 2,486.4 2,171.3
Other pharmaceuticals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266.8 268.8 214.4
Total human pharmaceutical products . . . . . . . . . . . . . . . . . . . . . . . 20,566.9 22,607.9 21,684.6
Animal health. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,036.5 1,678.6 1,391.4
Total segment revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 22,603.4 $ 24,286.5 $ 23,076.0
Segment profits
Human pharmaceutical products. . . . . . . . . . . . . . . . . . . . . . . . . . . $ 4,393.4 $ 5,837.9 $ 6,516.3
Animal health. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 508.1 301.0 250.9
Total segment profits. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 4,901.5 $ 6,138.9 $ 6,767.2
Reconciliation of total segment profits to consolidated income
before taxes
Segment profits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 4,901.5 $ 6,138.9 $ 6,767.2
Other profits (losses)
Income related to prepayment of Amylin's obligation (Note 4). . . 787.8 — —
Acquired in-process research and development (Notes 3 and 4) . —(388.0) (50.0)
Asset impairments, restructuring, and other special charges
(Note 5) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (281.1) (401.4) (192.0)
Total consolidated income before taxes. . . . . . . . . . . . . . . . . . . . . . . . $ 5,408.2 $ 5,349.5 $ 6,525.2
For internal management reporting presented to the chief operating decision maker, certain costs are fully
allocated to our human pharmaceutical products segment and therefore are not reflected in the animal health
segment's profit. Such items include costs associated with treasury-related financing, global service centers,
certain acquisition-related transaction costs, and inventory valuation adjustments.
(Dollars in millions) Year Ended December 31 2012 2011 2010
Geographic Information
Revenue—to unaffiliated customers(1)
United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 12,313.1 $ 12,977.2 $ 12,865.6
Europe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,259.7 5,290.9 5,106.4
Japan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,246.2 2,104.1 1,616.6
Other foreign countries. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,784.4 3,914.3 3,487.4
Revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 22,603.4 $ 24,286.5 $ 23,076.0
Long-lived assets(2)
United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 5,064.7 $ 5,485.3 $ 5,333.9
Europe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,281.1 2,220.2 2,250.7
Japan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101.5 102.9 101.2
Other foreign countries. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,543.2 1,564.0 1,588.4
Long-lived assets. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 8,990.5 $ 9,372.4 $ 9,274.2
1 Revenue is attributed to the countries based on the location of the customer.
2 Long-lived assets consist of property and equipment and certain sundry assets.